Cargando…

Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management

Patients with non-transfusion-dependent thalassemia (NTDT) experience many clinical complications despite their independence from frequent transfusions. Morbidities in NTDT stem from the interaction of multiple pathophysiological factors: ineffective erythropoiesis, iron overload (IOL), and hypercoa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sleiman, Joseph, Tarhini, Ali, Bou-Fakhredin, Rayan, Saliba, Antoine N., Cappellini, Maria Domenica, Taher, Ali T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796131/ https://www.ncbi.nlm.nih.gov/pubmed/29316681 http://dx.doi.org/10.3390/ijms19010182

Ejemplares similares

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2022)

Treating iron overload in patients with non-transfusion-dependent thalassemia
por: Taher, Ali T, et al.
Publicado: (2013)

Redox Balance in β-Thalassemia and Sickle Cell Disease: A Love and Hate Relationship
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2022)

Thalassemia in the emergency department: special considerations for a rare disease
por: Saliba, Antoine N., et al.
Publicado: (2020)

2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia
por: Farmakis, Dimitrios, et al.
Publicado: (2022)

Deferasirox: Over a Decade of Experience in Thalassemia
por: Moukalled, Nour M., et al.
Publicado: (2018)

How I treat non-transfusion-dependent β-thalassemia
por: Saliba, Antoine N., et al.
Publicado: (2023)

CYP450 Mediates Reactive Oxygen Species Production in a Mouse Model of β-Thalassemia through an Increase in 20-HETE Activity
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2021)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
por: Musallam, Khaled M., et al.
Publicado: (2023)

Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions
por: Saliba, Antoine N, et al.
Publicado: (2015)

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
por: Musallam, Khaled M, et al.
Publicado: (2023)

β-Thalassemia: New Therapeutic Modalities, Genetics, Complications, and Quality of Life
por: Karimi, Mehran, et al.
Publicado: (2012)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update
por: Iolascon, Achille, et al.
Publicado: (2019)

Iron overload across the spectrum of non‐transfusion‐dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions
por: Porter, John B., et al.
Publicado: (2016)

Right in time: Mitapivat for the treatment of anemia in α- and β-thalassemia
por: Musallam, Khaled M., et al.
Publicado: (2022)

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
por: Taher, Ali T, et al.
Publicado: (2013)

Coagulopathy in Beta-Thalassemia: Current Understanding and Future Perspectives
por: Cappellini, M. Domenica, et al.
Publicado: (2009)

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
por: Taher, Ali T., et al.
Publicado: (2013)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Untreated Anemia in Nontransfusion-dependent β-thalassemia: Time to Sound the Alarm
por: Musallam, Khaled M., et al.
Publicado: (2022)

Deep venous thrombosis and pulmonary embolism after COVID-19 mRNA vaccination
por: Atoui, Ali, et al.
Publicado: (2022)

Manifestation of paroxysmal nocturnal hemoglobinuria after COVID-19 mRNA vaccination
por: Jarrah, Kawthar, et al.
Publicado: (2022)

Complications in patients with transfusion dependent thalassemia: A descriptive cross‐sectional study
por: Faranoush, Mohammad, et al.
Publicado: (2023)

Complications of Transfusion-Dependent β-Thalassemia Patients in Sistan and Baluchistan, South-East of Iran
por: Yaghobi, Maryam, et al.
Publicado: (2017)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
por: Taher, Ali T., et al.
Publicado: (2023)

S270: TRANSFUSION INDEPENDENCE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA
por: Locatelli, Franco, et al.
Publicado: (2023)

P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
por: Kuo, K, et al.
Publicado: (2022)

Pulmonary Functions in Transfusion-Dependent Thalassemia
por: Chandra, Jagdish, et al.
Publicado: (2022)

Transfusion Complications in Thalassemia: Patient Knowledge and Perspectives
por: Patterson, Sashoy, et al.
Publicado: (2022)

Hemorheological profiles and chronic inflammation markers in transfusion-dependent and non-transfusion- dependent thalassemia
por: Caprari, Patrizia, et al.
Publicado: (2023)

Non-Transfusion-Dependent Thalassemia: A Panoramic Review
por: Shash, Hwazen
Publicado: (2022)

Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia
por: Musallam, Khaled M., et al.
Publicado: (2021)

Validation of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO(©))
por: Taher, Ali, et al.
Publicado: (2018)

Alloimmunization among transfusion-dependent thalassemia patients
por: Sadeghian, Mohammad Hadi, et al.
Publicado: (2009)

Glomerular and Tubular Functions in Transfusion-Dependent Thalassemia
por: Sookaromdee, Pathum, et al.
Publicado: (2018)

Quality of life in transfusion-dependent thalassemia patients
por: Alzahrani, Rizqallah A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_93p7iq8gnjl6t74fnkuob96eeh